title: [The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].
abstract: The use of DMD in treatment of multiple sclerosis (MS) with exacerbations allows to decrease significantly frequency of exacerbations and progression rate of inevitable neurological deficits resulting in disability, i.e. progression of pathological process, that is confirmed by brain and spinal cord MRI. Efficacy and safety of this method is also confirmed by multiple randomized clinical trials. Treatment with DMD should be done by neurologists trained in the field of diagnosis and management of MS. It can be widely used all over the country.
mesh_terms: D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods*; D016899:Interferon-beta / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*; D012426:Russia
chemical_list: D007155:Immunologic Factors; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta